About DNA primase large subunit
DNA primase large subunit (PRIM2) is a protein
from Homo sapiens identified by UniProt accession
P49643, 509 residues long.
MolForge cross-references it against 0 known binders and
307 disease associations.
Target properties
| Protein name | DNA primase large subunit |
| UniProt accession | P49643 |
| Gene | PRIM2 |
| Organism | Homo sapiens |
| Length | 509 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (307)
Diseases linked to this target (Open Targets).
- acute myeloid leukemia · score 0.60
- non-small cell lung carcinoma · score 0.60
- acute lymphoblastic leukemia · score 0.60
- pancreatic carcinoma · score 0.59
- chronic lymphocytic leukemia · score 0.59
- ovarian carcinoma · score 0.57
- breast carcinoma · score 0.57
- adult acute lymphoblastic leukemia · score 0.56
- leukemia · score 0.56
- neoplasm · score 0.56
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P49643-F1 | alphafold | PREDICTED | 80.63 | — |
Amino-acid sequence (509 residues)
MEFSGRKWRK LRLAGDQRNA SYPHCLQFYL QPPSENISLI EFENLAIDRV KLLKSVENLG VSYVKGTEQY QSKLESELRK LKFSYRENLE DEYEPRRRDH ISHFILRLAY CQSEELRRWF IQQEMDLLRF RFSILPKDKI QDFLKDSQLQ FEAISDEEKT LREQEIVASS PSLSGLKLGF ESIYKIPFAD ALDLFRGRKV YLEDGFAYVP LKDIVAIILN EFRAKLSKAL ALTARSLPAV QSDERLQPLL NHLSHSYTGQ DYSTQGNVGK ISLDQIDLLS TKSFPPCMRQ LHKALRENHH LRHGGRMQYG LFLKGIGLTL EQALQFWKQE FIKGKMDPDK FDKGYSYNIR HSFGKEGKRT DYTPFSCLKI ILSNPPSQGD YHGCPFRHSD PELLKQKLQS YKISPGGISQ ILDLVKGTHY QVACQKYFEM IHNVDDCGFS LNHPNQFFCE SQRILNGGKD IKKEPIQPET PQPKPSVQKT KDASSALASL NSSLEMDMEG LEDYFSEDS
Explore DNA primase large subunit with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets